Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Kezar Life Sciences, Inc.
< Previous
1
2
Next >
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
October 10, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
October 04, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
September 30, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 10, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 07, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
May 29, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 06, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 08, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 14, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 08, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
February 26, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 03, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 09, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
October 03, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
September 20, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
August 31, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 07, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 05, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
March 14, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
March 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023
March 06, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Tickers
KZR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.